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Abstract
Introduction: Benign prostatic hyperplasia (BPH) is a common condition affecting older men. Bothersome symptoms can progress to
serious complications such as acute urinary retention (AUR) requiring surgical intervention. Dutasteride, a dual 5-alfa-reductase (5AR)
inhibitor (5ARI), is a recently introduced therapy for the treatment of BPH.
Aims: The objective of this article is to review the evidence for the treatment of BPH with dutasteride. 
Evidence review: Evidence from large clinical studies shows that men with an enlarged prostate achieve a measurable decrease in
prostate volume by up to 26% after 4 years of treatment with dutasteride and urinary symptoms improve after 6 months of treatment.
This is achieved by rapid suppression (through inhibition of 5AR) of the principal androgen (dihydrotestosterone or DHT) responsible for
stimulating prostatic growth. Evidence suggests that dutasteride treatment results in a reduction in risk (rather than delay) of the most
serious complications including episodes of AUR and the need for BPH-related surgery. Early symptom relief has been achieved with
the combination of an alfa blocker and dutasteride. There is good evidence that dutasteride is well tolerated; side effects limited to sexual
dysfunction (reduced libido, impotence, and gynecomastia) are more common compared with placebo but occur with a similar incidence
to finasteride, another 5ARI. No pharmacoeconomic evidence from studies with dutasteride has so far been published. 
Clinical value: In conclusion, dutasteride is a valuable treatment option in men with moderate to severe BPH. Reductions in prostate
volume lead to symptom relief and serious complications appear to be reduced.
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Core evidence clinical impact summary for dutasteride in benign prostatic hyperplasia
Outcome measure Evidence  Implications
Patient-oriented evidence
Detectable symptom relief Substantial Effective treatment; delay in onset of action may be reduced by short-term combination with
an alfa blocker
Avoidance of surgery Clear Avoidance of one of the most costly complications associated with the progression of benign
prostatic hyperplasia
Reducing the risk of acute urinary retention Clear Avoidance of a serious acute complication of benign prostatic hyperplasia which requires
prompt medical intervention 
Tolerability Substantial Adverse events are few and reversible. Although prostate-specific antigen levels are reduced,
the “doubling rule” can be used and dutasteride use does not appear to interfere with the
detection of prostate cancer 
Disease-oriented evidence
Prostate gland size reduction  Substantial Fundamental outcome in treating the disease rather than just providing symptomatic relief
Dihydrotestosterone suppression Clear Reduced levels of the principal androgen responsible for prostatic growth 
Economic evidence
Cost effectiveness No evidence Studies required 
     Scope, aims, and objectives
Benign prostatic hyperplasia (BPH) is a common condition in older
men. It is characterized by the presence of troublesome lower
urinary tract symptoms (LUTS) which may be due to a number of
factors. This condition, which can significantly affect quality of life, is
becoming more prevalent as the population ages. There are a
number of strategies for the treatment of BPH including surgical
interventions and drug therapy. However, all of these interventions
have a variety of advantages and disadvantages which will influence
decisions made by patients and clinicians for the management of
the condition. Dutasteride, a dual 5-alfa-reductase (5AR) inhibitor
(5ARI), was introduced in 2002 for the treatment of BPH. 
The objective of this review is to provide an evidence-based
appraisal of dutasteride for the treatment and management of BPH. 
Methods
Medical literature databases were searched for appropriate
articles relating to dutasteride for the treatment of BPH. A search
of the following databases was conducted on February 15, 2005
using the search terms “dutasteride; benign prostatic hyperplasia
OR BPH AND guidelines” published between January 1990 and
January 2005 (inclusive):
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
• EMBASE, http://www.datastarweb.com
• BIOSIS, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effectiveness (DARE),
http://www.york.ac.uk/inst/crd/darehp.htm
• Cochrane Database of Systematic Reviews (CDSR),
www.cochrane.org/index0.htm
• Clinical Evidence, http://www.clinicalevidence.com
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk
• National Guideline Clearing House, www.guideline.gov
A total of 77 articles (including abstracts from meetings and full
publications) was identified and any animal, in-vitro studies, and
non-English articles were excluded. 
Table 1 summarizes the levels of evidence of 34 articles selected
from the 77 publications identified by the search strategy. No
systematic reviews were identified for the use of dutasteride in the
treatment of BPH. Most articles were of level 2 evidence, i.e.
randomized controlled studies either reported in meeting
abstracts or full publications. Four articles reported 2-year open-
label extension data from pooled randomized controlled studies
and were classified as level 3 evidence. No articles were identified
relating to pharmacoeconomic outcomes with dutasteride. 
Disease overview
BPH is a common age-related condition in men. Clinical and
histopathologic data suggest that 40–70% of men aged 60–70
years are affected, and this rises to more than 80% in men over
80 years (Djavan 2002; Dull et al. 2002). Therefore, as the
proportion of older people in the population grows then the
prevalence of BPH is set to increase. 
Although BPH is not a life-threatening disorder, bothersome LUTS
can seriously affect patient quality of life. The condition is
progressive and may lead to acute urinary retention (AUR), one of
the most significant complications of long-term BPH. Analysis of
placebo-treated groups from several multinational clinical trials
has shown that prostate volume and serum prostate-specific
antigen (PSA) levels are strong predictors of AUR in men with
LUTS and clinically diagnosed BPH who were screened for
prostate cancer (Roehrborn 2001; Roehrborn et al. 2001). It has
been estimated that the incidence rate for AUR is between 5 and
25 per 1000 years (or 0.5–2.5% per year) (Roehrborn 2001). The
risk is cumulative and increases with age. This complication is
one of the major factors that influences the need for surgery.
Furthermore, these patients have a high risk of developing
complications after prostatectomy. A prospective cohort study
assessed complication rates and symptomatic outcomes in 3966
men undergoing prostatectomy (Pickard et al. 1998). When
compared with those patients who underwent elective
prostatectomy for alleviation of symptoms alone, men presenting
with AUR had an excess risk of mortality and morbidity. Although
the men with AUR were generally older, had larger prostate
glands, and had more comorbidities, these factors did not fully
explain the excess risk.
From both the patient and the economic points of view AUR and
BPH-related surgery are considered to be the most significant
long-term risks of BPH. A recent discrete choice study in the UK
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Number of records
Category Full papers Abstracts
Initial search 41 36
records excluded 31 12
records included 10 24
Additional studies identified 11
Level 1 clinical evidence 0 0
Level 2 clinical evidence 9 23
Level ≥3 clinical evidence 22
trials other than RCT 0 0
case studies 0 0
Economic evidence 0 0
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trials.
Table 1 | Evidence base included in the review 
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showed that the respondents were willing to wait 13, 2, and 8
months longer for symptom improvement in exchange for
reduced prostate size, and an absolute 1% decrease in the risks
of AUR and surgery, respectively (Watson et al. 2004). 
There are two components (one static, the other dynamic) of
bladder outlet obstruction which are believed to contribute to
LUTS. Smooth muscle tone in the bladder, prostatic urethra,
prostate gland, and prostatic capsule is the dynamic component
and accounts for up to 40% of the obstruction seen in BPH (de la
Rosette et al. 2002). The static component of bladder outlet
obstruction is prostate enlargement characterized by the increase
in total volume and the transitional zone volume of the prostate
gland. Medical treatments for BPH target either the dynamic or
the static component of bladder outlet obstruction.
The pathophysiology of BPH is poorly understood.
Nevertheless it is clear that proliferation of the prostatic tissue
leading to enlargement is an age-dependent process which can
restrict urine outflow. The principal stimulus for prostatic
hyperplasia in later years is the androgen dihydrotestosterone
(DHT). Testosterone is converted via 5AR to DHT and inhibition
of this process leads to reduced levels of serum and
intraprostatic DHT. Two isoforms (type 1 and type 2) of 5AR
exist; type 2 is found in male genitalia and the prostate while
type 1 is present in skin, liver, prostate, and kidney (Clark et al.
2004). DHT is essential for normal masculinization of the
external genitalia and maturation of the prostate gland during
development. In later life it is the principal androgen
responsible for prostatic growth and so reducing serum DHT
levels can result in a clinically measurable decrease in prostate
volume over time through increased epithelial apoptosis. Thus
inhibition of 5AR targets the static component (prostate
enlargement) of bladder outlet obstruction.
Histologic changes in prostate tissue usually develop initially in
men over 40 years and by the age of 60 years the prevalence of
this change is more than 50% rising to 90% by 85 years
(Roehrborn et al. 2003c). At present the best documented risk
factors for BPH are age and functioning testes. 
Diagnosis of BPH
An early accurate diagnosis of BPH is important for determining
the most appropriate treatment option and maximizing the
treatment outcomes. The presence of LUTS is not specific or
exclusive to BPH and it is important to exclude other conditions
which may be responsible for these symptoms. In addition, the
presence of LUTS does not necessarily indicate an enlarged
prostate and BPH can also exist in the absence of LUTS. 
Clinical practice guidelines for the diagnosis and management
of BPH have been produced and recently updated in the USA
(Roehrborn et al. 2003c) and Europe (Madersbacher et al.
2004). Most guidelines stipulate that an initial evaluation should
involve taking a detailed medical history focusing on the urinary
tract coupled with a digital rectal examination (DRE) of the
prostate. Other recommended tests include uroflowmetry
[including volume of postvoid residual (PVR) urine], urinalysis,
measurement of creatinine and serum PSA, and symptom
assessment with a validated questionnaire. A questionnaire
commonly used to assess and quantify patient symptoms is the
International Prostate Symptom Score (I-PSS) which consists
of eight questions; seven questions investigate urinary
symptoms and one explores the quality of life [the American
Urological Association (AUA)-Symptom Index; AUA-SI is
equivalent to the first seven questions of the I-PSS, but does
not assess quality of life]. When compared with an informal
discussion this instrument provides a superior assessment of
symptom severity and frequency. Completion of the
assessment provides a classification of disease severity
ranging from mild, moderate, or severe (Table 2). 
Taken together, the various recommended diagnostic
assessments are designed to indicate or exclude the presence of
prostate cancer, estimate the size of the prostate gland, and
establish the severity and degree of bother caused by BPH
symptoms. The uroflowmetry studies are considered to be the
best noninvasive urodynamic tests to determine obstruction of
the lower urinary tract. 
Current therapy options
The aim of treating BPH is to relieve LUTS and reduce the risk
of AUR and BPH-related surgery which all affect patient quality
of life. Factors that need to be taken into account when
considering treatment options include the severity of symptoms,
prostate size, and patient preferences. There are three courses
of action for the management of this condition: watchful waiting,
medical therapy, and surgical or minimally invasive
interventions. Updated treatment guidelines based on recent
clinical data with these options have been published (Roehrborn
et al. 2003c; Madersbacher et al. 2004). Medical therapies are
summarized in Table 3. 
Watchful waiting
Watchful waiting is recommended for patients with mild
symptom scores (typically ≤7; see Table 2) that do not affect
daily life activities. Although the patient receives no active
treatment for BPH, simple changes in lifestyle such as
decreasing alcohol and caffeine intake, and fluid intake before
bedtime may reduce bothersome symptoms (Madersbacher et
al. 2004). It is vital that patients managed with watchful waiting
are regularly followed up by their physician to monitor any
progression (or remission) of the condition. 
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Symptom score Symptom severity
0–7 Mild
8–19 Moderate
20–35 Severe
Table 2 | Categories of symptom severity described by the
International Prostate Symptom Score (I-PSS)
 Medical therapy
Medical therapies can provide significant relief from symptoms
with less trauma compared with surgical treatment. Thus medical
therapies are an appropriate option for patients with
uncomplicated BPH with moderate to severe symptoms. 
The alfa blockers (alfa1-adrenoceptor antagonists), such as
doxazosin, relieve the dynamic component of bladder outlet
obstruction through their effect on blocking alfa1-adrenoceptor-
mediated contraction of prostatic smooth muscle and the bladder
neck. These agents can improve BPH symptoms rapidly (within
2–4 weeks) and this also allows the treatment to be evaluated and
modified relatively quickly. Although use of an alfa blocker can
delay BPH-related surgery and the incidence of AUR, risk of these
events still occurring has been shown to remain unaltered after 4.5
years treatment with doxazosin (McConnell et al. 2003). It remains
to be determined whether or not this is true for the newer alfa
blockers. Side effects encountered with these agents include
fatigue, asthenia, ejaculatory problems, and postural hypotension.
These can affect a significant number of patients; however, they
may be minimized by slow titration and by bedtime administration.
In order to minimize the side effects of the nonselective alfa
blockers (e.g. doxazosin, prazosin, and terazosin) a highly
selective alfa1A-adrenoceptor antagonist, tamsulosin, has been
developed. Although it is not associated with hypotension it is
more costly compared with the nonselective alfa blockers. 
The 5ARIs target prostate enlargement which is the static
component of bladder outlet obstruction. There are two 5ARIs
currently available, finasteride and dutasteride. Finasteride
selectively inhibits type 2 5AR at therapeutic doses while
dutasteride inhibits both type 1 and type 2 isoforms (Clark et al.
2004). In theory the greater suppression of DHT achieved from
inhibition of both 5AR isoforms could result in greater efficacy
than that with just selective type 2 inhibition as circulating DHT
generated by peripherally type 1 5AR may still influence prostate
growth (Bramson et al. 1997). 
Finasteride was the first 5ARI introduced for the treatment of
BPH. During a 4-year placebo-controlled study finasteride
treatment reduced the risk of AUR and the need for surgery by
more than 50%, and significantly improved symptom scores,
improved urinary flow rates, and reduced prostate volume (all
P<0.001) compared with placebo (McConnell et al. 1998). Side
effects are associated with sexual function and include erectile
and ejaculatory dysfunction, and decreased libido; however,
these are reversible on cessation of treatment and the incidence
of newly reported events decreases after the first year. 
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Option Advantages Disadvantages Comments
α α blockers
Alfuzosin Rapid symptom relief Risk of dizziness, postural
hypotension, and abnormal
ejaculation
No effect on PSA
Titration required at start of therapy
Doxazosin Rapid symptom relief Risk of dizziness, postural
hypotension, and abnormal
ejaculation
No effect on PSA
Titration required at start of therapy
Prazosin  Rapid symptom relief
Low acquisition cost
Risk of dizziness, postural
hypotension, and abnormal
ejaculation
Rarely used
No effect on PSA
Titration required at start of therapy
Tamsulosin Selective α1A antagonist
Rapid symptom relief 
No antihypertensive effect
Risk of abnormal ejaculation
High acquisition cost
No effect on PSA
Terazosin Rapid symptom relief Risk of dizziness, postural
hypotension, and abnormal
ejaculation
No effect on PSA
Titration required at start of therapy
5α α-reductase inhibitors
Dutasteride Reduces prostate size thereby treating
the underlying condition
Titration not required at start of therapy
>90% inhibition of circulating DHT
Gradual onset of action
Reversible impotence; decreased
libido and ejaculation
Reduces PSA levels (prostate cancer detection unaffected)
Generally well tolerated
Finasteride Reduces prostate size thereby treating
the underlying condition
Titration not required at start of therapy
~70% inhibition of circulating DHT
Gradual onset of action
Reversible impotence; decreased
libido and ejaculation
Reduces PSA levels (prostate cancer detection unaffected)
Generally well tolerated
DHT, dihydrotestosterone; PSA, prostate-specific antigen.
Table 3 | Summary of medical options for the treatment of benign prostatic hyperplasia
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Finasteride treatment also lowers serum PSA levels by about
50%. In patients treated with finasteride, serum PSA levels
should be multiplied by 2 (the “doubling rule”) and then
compared with the normal ranges for untreated men. Data from
the PLESS (Proscar Long-term Efficacy and Safety Study) trial
involving 3040 men have demonstrated that this approach
preserves the value of PSA as a tool for prostate cancer
detection (by prompting prostate biopsy for further investigation)
(Andriole et al. 1998). 
The attributes of a 5ARI (dutasteride) and alfa blockers were
investigated in a discrete choice study in community dwelling
men (>40 years) in the UK (Watson et al. 2004). Using
willingness to pay as a measure of preference for the defined
drug profiles, respondents were worse off (by almost £12
monthly) if they received alfa blockers compared with no
medication. In contrast, if respondents were on 5ARIs they were
better off by £19, demonstrating a preference for the attributes
of this treatment. 
The combination of an alfa blocker and 5ARI in a 4.5-year study
has been shown to be more effective in preventing the
progression of BPH than the single therapies (McConnell et al.
2003). In this study, the National Institutes of Health (NIH)
Medical Therapy of Prostatic Symptoms (MTOPS) trial, overall
progression was defined as a ≥4 point increase in AUA-SI
score, AUR, urinary incontinence, renal insufficiency, or
recurrent urinary tract infection. When compared with placebo
treatment, the combination drug regimen reduced the risk of
overall BPH progression by 67%, compared with 39% for
doxazosin alone and 34% for finasteride alone (P<0.001 for
each pairwise comparison of combination therapy vs
monotherapy). Symptom scores were significantly improved by
combination therapy, finasteride, or doxazosin (P<0.001 for all
treatments); combination therapy was superior to both
doxazosin (P=0.006) and finasteride (P<0.001) alone. However,
the risks of AUR and the need for BPH-related surgery were
significantly reduced by combination therapy and finasteride
(P<0.001 for both treatments), but not by doxazosin (McConnell
et al. 2003).
Surgical treatment 
The most well-established treatment option for BPH is surgery.
This intervention is recommended in patients with complicated
BPH or if previous medical treatments have failed, leaving the
patient with bothersome voiding symptoms such that their quality
of life is seriously affected. Transurethral resection of the prostate
(TURP) has become a well-established standard treatment for
BPH. However, surgery can be associated with significant short-
and long-term morbidity (bleeding, urinary tract infection,
retrograde ejaculation, and urethral strictures), and repeated
treatment may be necessary in up to 5–15% of patients within 8
years (Zlotta & Djavan 2002). In addition, TURP may not be a
suitable treatment for some patients who wish to avoid an
invasive surgical procedure or for whom surgery may pose
excessive risks. These factors have led to a number of recent
developments aimed at achieving the benefits of TURP but at
lower costs and with less morbidity. Thus minimally invasive
therapy (using thermal energy sources to produce coagulation
necrosis of prostate tissue) and surgical endoscopic techniques
are now available. 
Minimally invasive therapies may reduce the need for general
anesthesia and are associated with a lower rate of repeat
procedure; nevertheless they do not necessarily reach the same
levels of symptom improvement as TURP. In fact these therapies
have often been evaluated in comparison with TURP, but it is
perhaps more appropriate that they should be compared against
medical therapies which are usually taken for long periods and
which reduce in part or delay the need for surgery. 
Other treatment options including transurethral needle ablation
(TUNA), transrectal high-intensity focused ultrasound, and
prostate stents have not been adequately assessed for long-term
benefits.
Clinical evidence with dutasteride in BPH
Most clinical trial data with dutasteride have been derived from
three parallel, randomized, placebo-controlled studies of 2 years’
duration [ARIA3001 (US only), ARIA3002 (US only), and ARIB3003
(19 countries)] involving 400 participating centers and 4325
patients. Results from these studies have been published and the
data have also been pooled as the inclusion and exclusion criteria
for the trials were identical. All three studies have continued with
2-year open-label extensions during which all patients received
dutasteride, thus providing up to 4 years of observational data.
Results from these studies have been published extensively in
meeting abstracts and full publications. 
These trials evaluated patient-oriented outcomes (such as
symptom relief, reduction in the risks of AUR and surgery), and
measurement of disease-oriented surrogate markers (e.g. serum
DHT levels), safety, and tolerability. Patient-oriented outcomes are
by definition not only important and relevant to patients but also
to clinicians for everyday practice.
Two studies have directly compared dutasteride with finasteride
(Clark et al. 2004; Hagerty et al. 2004). In addition, a combination
study (SMART-1) with the alfa blocker tamsulosin has also been
conducted (Barkin et al. 2003). A large multinational 4-year
randomized study, COMBAT [Combination of Avodart®
(dutasteride) And Tamsulosin] is underway and is expected to
elucidate the effects of combination therapy for patients with
symptomatic BPH at high risk of disease progression (Kaplan
2004). Dutasteride has not been compared against an alfa blocker
for the treatment of BPH in any studies identified.
Reduction in the risk of AUR and BPH-related surgery 
Pooled results from the ARIA3001, ARIA3002, and ARIB3003
randomized controlled trials provide strong evidence that both the
incidence of surgical interventions and episodes of AUR are
reduced by dutasteride treatment (Table 4). At the end of the 2-
year double-blind phase of these studies, the reduction in risk of
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                      BPH-related surgical intervention was 48% and the risk reduction
of AUR was 57% compared with placebo (Roehrborn et al.
2002c). This effect was maintained for a further 2 years of
observation, representing good level 3 evidence. Although the 2-
year extensions were not placebo controlled, the low rates of
surgical or AUR events suggest the benefit in attenuating the
progression of BPH with dutasteride treatment for up to 4 years. 
Symptom relief 
There is evidence from pooled data from three studies that
dutasteride provides relief from the symptoms of BPH (Table 5).
Symptom relief has been measured by improvements in patient-
reported AUA-SI and BPH-Impact Index (BII) scores and clinically
measured uroflowmetry (Qmax). 
In the pooled studies AUA-SI scores improved significantly
compared with placebo (P<0.001) from 6 months onwards, but a
change in baseline was demonstrated as early as 3 months in one
study (Roehrborn et al. 2002c). After 4 years’ treatment with
dutasteride AUA-SI improved by 6.5 points compared with baseline
(Debruyne et al. 2004). Not only is this a statistically significant
improvement compared with baseline (P<0.001) and placebo
(P<0.001) treatment, but this change is also in excess of that
defined as a clinically relevant decrease in symptoms (≥3.1 points)
and one that would be perceptible to patients (Barry et al. 1995).
Qmax improved with dutasteride and significant differences
(P≤0.006) compared with placebo were seen as early as 1 month
after starting treatment and at all measured endpoints up to 2
years. In each of the three individual studies the effect on Qmax
became statistically significant after 3 months’ treatment with
dutasteride compared with placebo (Roehrborn et al. 2002c). 
A comparison of dutasteride and finasteride (doses not stated) on
symptom relief has been published as a recent meeting abstract.
This single-center 3-month prospective study recruited 240
consecutive men with benign prostatic enlargement and
symptomatic BPH who were assigned to dutasteride (n=120) or
finasteride (n=120) (Hagerty et al. 2004). Patients receiving
dutasteride had a greater reduction in AUA-SI scores compared
with those receiving finasteride: 36 vs 22 had a 1-point
improvement, 14 vs five had a 2-point improvement, two vs one
had a 3-point improvement, and 68 vs 92 had no change in their
score. The estimated difference between the two treatment
groups for the proportion of subjects with an improvement in
AUA-SI score was 20% (95% confidence intervals 7–32.5%;
P<0.0016). Although the magnitude of response for dutasteride
was greater than finasteride it is unclear whether this is due to a
difference in time of onset of action. 
EPICS (Enlarged Prostate International Comparator Study) was a
short-term direct comparator trial between dutasteride (0.5 mg) and
finasteride (5 mg) in men with BPH (Gilling et al. 2005). Following a
4-week placebo run-in period, 1630 patients (eligibility; age >50
years, AUA-SI ≥12, prostate volume ≥30 mL, PSA 1.5–10 ng/mL,
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Level of
evidence
Reference Design Treatment and
mean dose
Outcome
Incidence
of AUR
Surgical intervention rate
2
2
a
Roehrborn et al.
2002c
Boyle et al. 2002b
2-y RCT (ARIA3001, 3002,
ARIB3003)
n=4325 (DUT n=2167,
placebo n=2158)
DUT (0.5 mg)
Placebo
4.2% (placebo) vs 1.8% (DUT),
57% risk reduction after 2 y
4.1% (placebo) vs 2.2% (DUT);
48% risk reduction after 2 y
2
a
2a
Boyle et al. 2003a
Boyle et al. 2003b
85% and 55% risk reduction with
DUT in patients with prostate
volume 30 to ≤40 mL and
≥40 mL, respectively
35% and 52% risk reduction with
DUT in patients with PV 30 to
≤40 mL and ≥40 mL, respectively
3 Debruyne et al.
2004
2-y OL phase (ARIA3001,
3002, ARIB3003)
n=4325 (DUT/DUT n=1188,
placebo/DUT n=1152)
DUT (0.5 mg) 5.1% (placebo/DUT) vs 2.4%
(DUT/DUT) after 4 y
4.5% (placebo/DUT) vs 2.6%
(DUT/DUT) after 4 y
3
a Emberton 2004 1.9% (placebo/DUT) vs
1.2% (DUT/DUT) (P=0.14) during
OL extension
0.8% for placebo/DUT and
DUT/DUT, no difference on
relative risk (P=0.95) during OL
extension
3 Roehrborn et al.
2004b
2-y OL phase (ARIA3001,
3002)
n=1570 (DUT/DUT n=792,
placebo n=778)
DUT (0.5 mg) 1.7% (placebo/DUT) vs 1.3%
(DUT/DUT)
0.6% (placebo/DUT) vs 0.6%
(DUT/DUT)
aAbstract.
DUT, dutasteride; DUT/DUT, dutasteride treatment continuing from RCT to OL phase; OL, open label; placebo/DUT, switch from placebo in RCT to DUT in OL phase; PV, prostate volume; RCT,
randomized controlled trial; y, year. 
Table 4 | Summary of outcomes with dutasteride for the treatment of benign prostatic hyperplasia (BPH); avoidance of BPH-related
surgical interventions and episodes of acute urinary retention (AUR)
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Qmax ≤15 mL/s) were randomized to dutasteride (n=813) or
finasteride (n=817) for 48 weeks. After 1 year similar improvements
from baseline in AUA-SI of 6.2 and 5.8 and in Qmax of 2.1 and
1.8 mL/s were seen with dutasteride and finasteride, respectively.
Given the gradual, progressive course of BPH and the mode of
action of 5ARIs major differences in efficacy would not necessarily
be seen in studies of up to 1-year duration (Gilling et al. 2005). 
There may be a delay of up to 6 months before 5ARIs improve
symptoms. In contrast, the onset of symptom relief with alfa
blockers is more rapid. The SMART-1 study (n=327 patients with
moderate to severe urinary symptoms, IPSS ≥12) was initiated to
investigate speed of symptom relief with tamsulosin combined
with dutasteride, then maintenance of effect following withdrawal
of the alfa blocker after 6 months (Barkin et al. 2003). There is
evidence that early symptom relief was achieved with this
combination, with 66% of men reporting improvement after 4
weeks. The study also showed that tamsulosin could be
withdrawn from the majority of men (77%) after 6 months with
maintenance or improvement of symptom relief. Of the subjects
with moderate baseline symptoms (IPSS <20), 84% switched to
dutasteride monotherapy with no noticeable deterioration in their
symptoms. A subgroup of patients (27%) with severe baseline
symptoms (IPSS ≥20) reported a higher rate of worsening of
symptoms when tamsulosin was withdrawn compared with
patients with moderate symptoms (42.5% vs 16%). Thus patients
with severe symptoms may benefit from longer combination
therapy but the study did not continue beyond 6 months to allow
this to be explored. 
Reduction in androgen levels and prostate gland size 
There is good evidence that dutasteride reduces the disease-
oriented outcome of prostate volume in men with BPH, as
measured by total prostate volume (TPV) and transition zone
volume (TZV) (Table 6). Reductions in mean TPV were evident
after 1 month, with further shrinkage as dutasteride treatment
continued, by up to 26.2% after 4 years (Roehrborn et al. 2004b).
An abstract report of these studies showed that, at 2 years, the
effect of dutasteride in reducing prostate volume was equal for
patients with smaller (30 to ≤40 mL) compared with larger
baseline prostate volume (≥40 mL) (Boyle et al. 2003a). These
data suggest that dutasteride may be initiated early in the time
course of BPH progression in order to limit prostate growth.
As discussed above, DHT is the principal androgen responsible
for stimulating prostatic growth. Dutasteride has been shown to
effectively reduce serum levels of DHT in a number of large
studies. The onset of suppression of DHT is rapid and ≥90%
reduction has been seen in 58% of patients after 1 month’s
treatment with dutasteride (Roehrborn et al. 2002c). After 4 years’
treatment with dutasteride, serum DHT levels were reduced by
≥90% in 87% of patients (Debruyne et al. 2004).
Dutasteride has also been shown to be more effective at
suppressing serum DHT levels compared with finasteride (Clark et
al. 2004). After 24 weeks of treatment, suppression of DHT was
statistically significantly greater with 0.5 mg dutasteride (94.7%
inhibition) compared with 5 mg finasteride (70.8% inhibition,
P<0.001). A greater proportion of dutasteride-treated patients also
achieved suppression of DHT levels by both >70% and >90%
compared with finasteride-treated patients (Roehrborn et al. 2003a).
These data demonstrate that dutasteride reduces circulating levels
of DHT to a greater extent than finasteride and that maximal
reduction of DHT is achieved in a larger proportion of patients thus
minimizing the influence of this androgen on prostate growth.
As well as reducing DHT levels in serum, dutasteride has been
shown to reduce intraprostatic levels of the androgen which is
important in the context of the underlying disease
pathophysiology. In a small randomized double-blind study
46 patients with biopsy-proven T1/T2 prostate cancer were
treated with placebo or dutasteride for up to 82 days prior to
radical prostatectomy (Andriole et al. 2003). Dutasteride
powerfully suppressed both serum and intraprostatic DHT by
96.7% and >97% respectively, compared with baseline and
placebo treatment (P<0.001). However, it should be noted that the
dose of dutasteride (5 mg) used in this study was 10-fold greater
than the recommended therapeutic dose. 
Effects on PSA levels 
Dutasteride treatment for 4 years resulted in the reduction in
serum PSA levels from baseline by 57% (Table 7). Most of this
reduction occurred within 1 year of treatment (Andriole & Kirby
2003). One concern with reducing PSA levels is the potential
masking of prostate cancer detection. Data from the 4-year
pooled analysis showed that 77% of the dutasteride-treated
patients with prostate cancer reported during the study had an
increase in PSA after nadir compared with 52% of patients with
no diagnosis of prostate cancer. Among dutasteride-treated
patients with no diagnosis of prostate cancer the median
maximum increase in PSA from nadir was 0.1 ng/mL compared
with 0.9 ng/mL in patients with a diagnosis of prostate cancer.
Monitoring PSA over time therefore allows a risk of prostate
cancer to be assessed (Roehrborn et al. 2004a). In addition,
dutasteride had no clinically meaningful effect on the free-to-total
(F/T) PSA ratio. Thus the utility of the sensitivity and specificity of
F/T PSA is maintained as a screen for detecting prostate cancer
in men treated with a 5ARI (Andriole et al. 2002). 
PSA values should be doubled for patients who have been treated
with dutasteride for at least 6 months to determine whether or not
isolated PSA levels fall within normal ranges in untreated men
(Andriole & Kirby 2003). As has been shown with finasteride, use
of the “doubling rule” preserves the usefulness of PSA for
detecting prostate cancer (Andriole et al. 1998). 
Safety and tolerability 
Results from observational studies provide good evidence of the
safety and tolerability of dutasteride in a large number of patients
treated over a long period of up to 4 years (Roehrborn et al.
2002c, 2004b; Andriole & Kirby 2003; Debruyne et al. 2004) (Table
8). In addition, up to 1 year’s comparative data with dutasteride
and finasteride have been obtained from two studies (ARI40001
Dutasteride | clinical impact review
Core Evidence 2005;1(2)
                   Dutasteride | clinical impact review
© 2005 Core Medical Publishing Limited 150
Level of
evidence
Reference Design Treatment
and
mean dose
Outcome
AUA-SI Qmax Symptom scores BII
2 Debruyne et
al. 2004
2-y RCT
(ARIA3001,
3002,
ARIB3003)
n=4325 (DUT
n=2167,
placebo
n=2158)
DUT (0.5 mg)
placebo
Change of –4.4 points
(DUT) vs –2.5 points
(placebo), P<0.001
after 2 y 
Change of +2.2 mL/s
(DUT) vs +0.6 mL/s for
(placebo) P<0.001
after 2 y
NR NR
2a Roehrborn et
al. 2002d 
Improved with DUT in
patients with enlarging
TPV and TZV vs placebo
Improved with DUT in
patients with enlarging
TPV and TZV vs placebo
NR Improved with DUT in
patients with enlarging
TPV and TZV vs placebo
2a
2a
Boyle et al.
2003a
Boyle et al.
2003b
Improved with DUT vs
placebo (P<0.001) with
baseline PV 30 to
≤40 mL and PV ≥40 mL 
Improved with DUT vs
placebo (P<0.001) with
baseline PV 30 to
≤40 mL and PV ≥40 mL
Improved with DUT vs
placebo (P<0.001) with
baseline PV 30 to
≤40 mL and PV ≥40 mL
2a Boyle et al.
2002a 
NR Change from baseline
(mL/s) improved with
DUT vs placebo; 0.8 vs
0.5, P=0.006 (after 1 mo);
1.3 vs 0.6, P<0.001 (3
mo); 2 vs 0.9, P<0.001
(2 y)
Change from baseline
improved with DUT vs
placebo –3.2 vs –2.5,
P<0.001 (6 mo); 4.6 vs
–2.3, P<0.001 (2 y)
BPH-specific health
status change from
baseline improved with
DUT vs placebo 0.63
vs –0.41, P=0.003 (at
6 mo); 1 vs –0.26,
P<0.001 (2 y)
2 O’Leary et al.
2003
2-y RCT
(ARIA3001,
3002,
ARIB3003)
n=4325 (DUT
n=2167,
placebo
n=2158)
DUT (0.5 mg)
placebo
NR NR Clinically relevant
improvement in BPH
health status from
6 mo
Improvement of 2.41
(DUT) vs 1.64 (placebo)
for patients with
significant symptom
burden after 2 y
2a Hagerty et al.
2004
3-mo
prospective
study 
n=240 (n=120
DUT, n=120
FIN)
DUT
FIN
Improvements by 1
point (30% vs 18%),
2 points (12% vs 4%),
and 3 points (2% vs 1%)
for DUT vs FIN
No change in score 57%
(DUT) vs 77% (FIN). DUT
vs FIN P<0.0016
NR NR NR
2
a Gilling et al.
2005
1-y study
(EPICS) n=1630
randomized
(n=813 DUT,
n=817 FIN),
n=1454
completed
DUT (0.5 mg)
FIN (5 mg)
Improvements from
baseline of 6.2 for DUT
vs 5.5 for FIN
Improvements from
baseline of 2.1 mL/s for
DUT vs 1.8 mL/s for FIN
NR NR
3 Roehrborn et
al. 2004b
2-y OL
extension
(ARIA3001,
3002)
n=2802
(DUT/DUT
n=792,
placebo/DUT
n=778)
DUT (0.5 mg) –6.1 (DUT/DUT) vs –5.3
points (placebo/DUT)
2.8 mL/s (DUT/DUT) vs
1.8 mL/s (placebo/DUT)
NR NR
continued opposite…
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Level of
evidence
Reference Design Treatment and
mean dose
Outcome
AUA-SI Qmax Symptom scores BII
3 Debruyne et
al. 2004
2-y OL
extension
(ARIA3001,
3002,
ARIB3003)
n=4325
(DUT/DUT
n=1188,
placebo/DUT
n=1152)
DUT (0.5 mg) –6.5 (DUT/DUT) vs
–5.6 points for
(placebo/DUT)
(P<0.001)
+2.7 (DUT/DUT) vs
+1.9 mL/s
(placebo/DUT)
(P<0.001)
NR NR
2
a Barkin et al.
2002
36-w RCT
(SMART-1)
n=327
DUT (0.5 mg)
and TAM
(0.4 mg)
vs DUT
(0.5 mg)
NR NR 66% patients on active
therapy reported
improvement in urinary
symptoms after 4 w
77% DUT patients vs
91% DUT/TAM
patients assessed their
urinary symptoms
better or no worse 6 w
after TAM withdrawal
NR
2 Barkin et al.
2003
NR NR Symptom
improvement
sustained in 93% of
patients 12 w after
TAM withdrawn 
84% patients with an
IPSS <20 who changed
to DUT monotherapy
(at week 24) switched
without a noticeable
deterioration in
symptoms
42.5% patients with
severe baseline
symptoms (IPSS ≥20)
who changed to DUT
monotherapy reported
worsening of
symptoms vs 16%
with moderate
baseline symptoms
(IPSS <20)
NR
3
a 2-y RCT plus
2-y OL
extension
(ARIA3002)
n=1362
DUT (0.5 mg) Improvement by
5.5 points (including
2 points improvement
in the OL phase) with
DUT/DUT during 4 y
Improved by 3 points
over 2 y with
placebo/DUT
(consistent with the
DUT/DUT response of
3.4 point improvement
in the first 2 y)
NR NR
aAbstract.
AUA-SI, American Urology Association Symptom Index; BII, BPH-Impact Index; DUT, dutasteride; DUT/DUT, dutasteride treatment continuing from RCT to OL phase; FIN, finasteride; IPSS,
International Prostate Symptom Score; NR, not reported; OL, open label; placebo/DUT, switch from placebo in RCT to DUT in OL phase; PV, prostate volume; Qmax, maximal flow rate (mL/s);
RCT, randomized controlled trial; TAM, tamsulosin; TPV, total prostate volume; TZV, transitional zone prostate volume; w, week; y, year. 
               1-year duration, and ARIA2001, a 24-week study) (Andriole &
Kirby 2003; Clark et al. 2004).
These studies show that the incidence of general adverse
events with dutasteride was similar to that with placebo. The
exception was an elevated incidence of sexually-related
adverse events which were seen more commonly with
dutasteride in the first 6 months of treatment compared with
placebo; impotence 4.7 vs 1.7% (P<0.05), decreased libido 3
vs 1.4% (P<0.05), ejaculation disorder 1.4 vs 0.5% (P<0.05),
and gynecomastia 0.5 vs 0.2% (not significant). The incidence
of these events (except impotence, 1.4 vs 1.5% for dutasteride
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Level of
evidence
Reference Design Treatment and
mean dose
Outcome
Prostate volume Androgen levels
2
2
a
Roehrborn et al.
2002c 
Tammela et al.
2004
2-y RCT (ARIA3001,
3002, ARIB3003)
n=4325 (DUT
n=2167, placebo
n=2158)
DUT (0.5 mg)
Placebo
NR Mean change of serum DHT from
baseline by –90.2% (DUT) vs +9.6%
(placebo) (P<0.001) after 2 y
58% patients achieved ≥90% DHT
reduction after 1 mo; 85% patients
achieved ≥90% DHT reduction after 1 y
with DUT
2 Debruyne et al.
2004
Mean change in TPV from baseline
–26% (DUT) vs +1.4% (placebo)
(P<0.001) after 2 y
2
a Roehrborn et al.
2002b
Mean change in serum DHT from
baseline –91% (DUT) vs +9.2%
(placebo) 
2
a
2a
Roehrborn et al.
2002a
Boyle et al. 2002a
Changes in TPV and TZV by 8.6% and
6.9% from baseline with DUT after 1
mo, and –28.5% vs 26.8%, respectively
at 2 y
NR
2
a
2a
Boyle et al. 2003a 
Boyle et al. 2003b
PV reduced by 26.1% with DUT for
patients with baseline prostate volume
30 to ≤40 mL and 26.9% for patients
with baseline PV ≥40 mL (P<0.001 vs
placebo) by 2 y
NR
2 Clark et al. 2004 24 w RCT
n=399 (ARIA2001)
DUT (0.001–5 mg)
FIN (5 mg)
placebo
NR Change in serum DHT –94.7% (DUT
0.5 mg), –70.8% (FIN), +1.6% (placebo),
(P<0.001 DUT vs placebo and FIN, FIN
vs placebo)
2
a Roehrborn et al.
2003b 
>90% DHT suppression with 85.4%
DUT patients vs 49% FIN patients. 
>70% DHT suppression with 100% DUT
patients vs 49% FIN patients
2
a Andriole et al.
2003
RCT n=46 (DUT
n=22, placebo
n=24) in men with
untreated T1/T2
PCa
DUT (5 mg)
Placebo
NR Serum DHT reduced from baseline by
96.7% (DUT) vs 1.4% (placebo) 
Intraprostatic DHT 0.095 ng/g (DUT) vs
6.49 ng/g (placebo); >97% reduction,
P<0.001)
3 Debruyne et al.
2004
2-y OL extension
(ARIA3001, 3002,
ARIB3003)
n=4325 (DUT/DUT
n=1188,
placebo/DUT
n=1152)
DUT (0.5 mg) TPV changes were
–27.3% (DUT/DUT) vs –21.7% for
(placebo/DUT) (P<0.001)
Mean change in serum DHT from
baseline was 95.3% for DUT/DUT vs
95.4% for placebo/DUT 
4-y treatment with DUT reduced DHT by
≥90% in 87% patients
3 Roehrborn et al.
2004b
Change in prostate volume –26.2%
(DUT/DUT) vs –20.7% (placebo/DUT)
NR
aAbstract.
DHT, dihydrotestosterone; DUT, dutasteride; DUT/DUT, dutasteride treatment continuing from RCT to OL phase; FIN, finasteride; mo, month; NR, not reported; OL, open label; PCa, prostate
cancer; placebo/DUT, switch from placebo in RCT to DUT in OL phase; PV, prostate volume; RCT, randomized controlled trial; TPV, total prostate volume; TZV, transitional zone prostate
volume; w, week; y, year.
Table 6 | Summary of outcomes with dutasteride for the treatment of benign prostatic hyperplasia (BPH); effect on
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and placebo, respectively) was <1% after 1 year’s treatment
suggesting that they were transient and reversible (Andriole
& Kirby 2003). 
The adverse event profile with clinically used doses of
dutasteride (0.5 mg/day) and finasteride (5 mg/day) were similar
(Clark et al. 2004). There were no significant differences in the
incidence of the most common adverse events between the
active treatment groups or placebo, other than an increased
reporting of altered libido among patients receiving finasteride or
dutasteride (≥0.5 mg/day). 
Resource utilization
Medical treatment for BPH requires lifetime medication. In
comparison, surgery is generally a one-off event which can be
costly due to the requirement for a stay in the hospital. It has been
estimated that the 5-year cost of treatment of BPH by TURP is
$US7334 compared with typical drug therapy costing $US6294
during the same time-period (Dull et al. 2002). A patient’s drug
treatment costs are likely to be stable but if a repeat procedure is
required then the cost of surgery effectively doubles. 
Because they alter the natural history of symptomatic BPH the
5ARIs are the only medical treatment for BPH that reduce
prostate volume, which may influence the need for surgery and
reduce the risk of AUR. Data obtained with dutasteride have
provided evidence that indicates both surgery and AUR can be
avoided. AUR is one of the most important complications with
BPH. At the very least the patient will present in pain with the
inability to urinate and will probably require catheterization in the
emergency room. Follow-up visits, catheter removal, and then
surgery are the likely costly sequelae of AUR. Clearly a treatment
that ultimately avoids, rather than just delays, the need for
managing AUR and surgery can have important implications in
resource utilization. Hospital resources are under greater pressure
as the population ages and so any treatment that can reduce this
burden is appealing. Furthermore, reducing the need for TURP
would have significant implications as it is the second most
common surgical procedure (after cataract extraction) in men
older than 65 years with 400 000 operations costing $US5 billion
per year (Oesterling 1995). 
Although dutasteride is effective in reducing the signs and
symptoms of BPH there is a delay in the onset of statistically
significant symptom relief of at least 3 months (Roehrborn et al.
2002c). This delay may be reduced by the short-term
combination of dutasteride with an alfa blocker. So far only the
effects of combining tamsulosin with dutasteride have been
reported (Barkin et al. 2002, 2003). Nevertheless it is possible
that other alfa blockers may be used in combination. For
example, doxazosin has been used in combination with
finasteride for the generation of rapid symptom relief. The AUA
guidelines note that the combination of an alfa blocker and a
5ARI is an appropriate and effective treatment for patients with
LUTS associated with demonstrable prostatic enlargement
(Roehrborn et al. 2003c). The cost of adding an extra treatment
to the patient’s medication has obvious implications to budgets
and resources.
The optimal period for continuing with an alfa blocker in
combination therapy is unclear. Whether it can be withdrawn after
short-term symptom relief has been achieved or continued
treatment is necessary remains to be determined. It is also
unclear as to whether or not combination therapy would lead to
improved compliance with drug treatment due to patients
perceiving improvements in treatment effects. 
Patient group/population
Dutasteride and finasteride have been recommended as
appropriate and effective treatments for patients with LUTS
associated with demonstrable prostatic enlargement (Roehrborn
et al. 2003c). This is because they affect the natural history of the
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Level of evidence Reference Design Treatment and mean dose PSA levels
2a Roehrborn et al. 2004a  2-y RCT (ARIA3001, 3002,
ARIB3003)
n=4325 (DUT n=2167,
placebo n=2158)
DUT (0.5 mg)
Placebo
Median max increase in PSA from nadir 0.1 ng/mL in
men with no PCa recorded as an AE over 4 y
(n=2124). Among those with PCa recorded as an AE
(n=43) the median max rise from nadir was 0.9 ng/mL
77% of men on DUT diagnosed with PCa had an
increase in PSA after reaching nadir
2
a Andriole et al. 2002 2-y RCT 
n=674 within ARIA3002
(DUT n=337, placebo
n=337)
DUT (0.5 mg)
Placebo
After 2 y the F/T PSA ratio changed by –4.7% (DUT)
vs +2% (placebo), P<0.05; maintaining the usefulness
of this parameter
3 Roehrborn et al. 2004b 2-y OL extension
(ARIA3001, 3002,
ARIB3003)
n=4325 (DUT/DUT n=792,
placebo/DUT n=778)
DUT (0.5 mg) Mean PSA reduced from 4.1 (baseline) to 1.7 ng/mL
(57.5% reduction) with DUT for 4 y
aAbstract.
AE, adverse events; DUT, dutasteride; F/T, free to total; OL, open label; PCa, prostate cancer; RCT, randomized controlled trial; y, year.
Table 7 | Summary of the outcomes associated with dutasteride and prostate-specific antigen (PSA)
                disease and affect its progression by limiting prostate
enlargement. The benefits of this may be seen in the reduced
occurrence of AUR and avoidance of surgery. 
Because 5ARIs are not as effective as alfa blockers (and have a
slower onset of action) for symptom relief they are not
recommended for the treatment of LUTS alone in men with no
prostatic enlargement. In this case alfa blockers are an
appropriate treatment option to manage troublesome symptoms
through the dynamic component of bladder outlet obstruction.
Prostate volume is reduced by 18–27% in men receiving 5ARIs for
up to 4 years, irrespective of baseline prostate volume (McConnell
et al. 1998; Roehrborn et al. 2004b). Early initiation of a 5ARI in
symptomatic men with enlarged prostates and a PSA level of
≥1.5 ng/mL has been proposed as a reasonable approach to
decreasing prostate volume and maintaining the reduction long
term (Roehrborn et al. 2004b). 
In addition to the demonstrable presence of an enlarged prostate
gland other factors may influence the choice of dutasteride for the
treatment of BPH for specific patient groups. Younger patients
with moderate or severe BPH may wish to avoid surgery yet
achieve symptom relief. Avoidance of troublesome side effects
and the maintenance of libido and sexual function are also factors
which will influence the choice of appropriate therapy. 
Dosage, administration, and formulations
Dutasteride (Avodart®) is indicated for the treatment of
symptomatic BPH in men with an enlarged prostate to improve
symptoms, reduce the risk of AUR, and reduce the risk of the need
for BPH-related surgery. It is contraindicated for use in women and
children and for patients with known hypersensitivity to
dutasteride, other 5ARIs, or any component of the preparation.
The recommended dose is one capsule (0.5 mg dutasteride) taken
orally once a day and may be administered with or without food. 
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Level of
evidence
Reference Design Treatment and
mean dose
Incidence of adverse events 
2 Andriole &
Kirby 2003
2-y RCT (ARIA3001,
3002, ARIB3003) 
n=4325 (DUT n=2167,
placebo n=2158)
DUT (0.5 mg)
Placebo
6-mo results: sexual AEs were more common with DUT vs placebo (impotence 4.7% vs
1.7%, P<0.05; decreased libido 3% vs 1.4%, P<0.05; gynecomastia 0.5% vs 0.2%, NS;
ejaculation disorder 1.4% vs 0.5%, P<0.05)
2-y results: sexual AEs with DUT vs placebo (impotence 0.8% vs 0.9%, NS; decreased
libido 0.3% vs 0%, NS; gynecomastia 0.6% vs 0.1%, P<0.05; ejaculation disorder 0.1%
vs 0%, NS)
2 Roehrborn
et al. 2002c
During 2-y treatment sexual AEs were more common with DUT vs placebo (impotence
7.3% vs 4%, decreased libido 4.2% vs 2.1%, gynecomastia 2.3% vs 0.7%, ejaculation
disorder 2.2% vs 0.8%; P<0.001 for all)
2
a Carson et
al. 2003
Maximal suppression of DHT with DUT does not increase the incidence of drug-related
sexual AEs and gynecomastia over that historically reported for other 5AR inhibitors
2 Clark et al.
2004
24 w RCT
n=399 (ARIA2001)
DUT (0.01–5 mg)
FIN (5 mg)
Placebo
Altered libido in 2% (placebo), 11% (DUT 0.5 mg), 13% (FIN) (P<0.05 vs placebo)
patients; impotence in 3% (placebo), 5% (DUT) and 11% (FIN) patients
2 Andriole &
Kirby 2003
1-y RCT (ARI4001)
n=1630 (DUT n=813,
FIN n= 817)
DUT (0.5 mg)
FIN (5 mg)
Sexual AEs, impotence 7% (DUT) vs 8% (FIN), decreased libido 5% (DUT) vs 6% (FIN),
gynecomastia 1% (DUT) vs 1% (FIN), ejaculation disorder 1% (DUT) vs 1% (FIN)
2
a
2
a
Clark et al.
2003
Clark &
Matsumoto
2003
RCT n=99 DUT (0.5 mg) 
FIN (5 mg)
placebo
No clinically significant changes from baseline in bone density, markers of bone
metabolism or lipid levels between treatment groups for <1 y and follow-up weeks 20–24
2 Andriole &
Kirby 2003 
36-w RCT (SMART-1)
n=327
DUT (0.5 mg) and
TAM (0.4 mg) vs
DUT (0.5 mg)
Ejaculation disorders were the only AEs considered to be at least possibly drug related
and occurring in ≥5% of patients
3 Roehrborn
et al. 2004b
2-y OL extension
(ARIA3001, 3002)
n=2802 (DUT/DUT
n=792, placebo/DUT
n=778)
DUT (0.5 mg) 1-y results: sexual AEs with DUT/DUT vs placebo/DUT (impotence 1.6% vs 3.1%,
decreased libido 0.5% vs 2.6%, gynecomastia 1.9% vs 1.5%, ejaculation disorder 0.3%
vs 1.3%)
2-y results: sexual AEs with DUT/DUT vs placebo/DUT (impotence 0.6% vs 0.4%,
decreased libido 0% vs 0.3%, gynecomastia 1% vs 1.1%, ejaculation disorder 0.5% vs
0.1%)
aAbstract.
5AR, 5-alfa-reductase; AE, adverse event; DHT, dihydrotestosterone; DUT, dutasteride; DUT/DUT, dutasteride treatment continuing from RCT to OL phase; FIN, finasteride; mo, month; NS, not
significant; OL, open label; placebo/DUT, switch from placebo in RCT to DUT in OL phase; RCT, randomized controlled trial; TAM, tamsulosin; w, week; y, year.
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Clinical value
There is now a range of options for the treatment of BPH,
including watchful waiting through to medical treatments,
minimally invasive therapies, and surgery. 
Men with mild BPH symptoms (as determined by AUA-SI) that are
not bothersome may undergo watchful waiting in order to monitor
any change in the condition. If there is progression to moderate or
severe symptoms then any of the current treatment options may
be considered. However, it is important for the physician and
patient to discuss the various options together so that an
appropriate treatment may be selected. 
During clinical development, dutasteride has been shown to improve
BPH symptoms and is also well tolerated. These findings have been
confirmed during large open-label extension studies continuing for at
least 2 years giving up to 4 years’ clinical data with dutasteride. These
observational studies have extended the findings that dutasteride
reduces the risk of the most serious complications associated with
BPH, i.e. AUR and the need for surgery. This is achieved by
dutasteride altering the natural history of BPH progression through
significant reductions in prostate volume (achieved by rapid and near
maximal suppression of circulating DHT levels). 
Because dutasteride acts on the static component of bladder
outlet obstruction, there is a delay in onset of symptom relief of
up to 6 months. The combination of dutasteride and an alfa
blocker (tamsulosin) has overcome this delay while limiting
disease progression. Clearly this approach has advantages in the
management of BPH. Up to 5 years follow-up data from the
MTOPS study have shown that the combination of a 5ARI
(finasteride) and alfa blocker was most effective in treating BPH
(McConnell et al. 2003). Recent treatment guidelines have used
these findings to recommend that combination therapy with
5ARIs and alfa blockers are more beneficial than monotherapy
(Roehrborn et al. 2003c; Madersbacher et al. 2004). 
In conclusion, dutasteride has a place in therapy for those
patients with a demonstrable prostate enlargement and the
presence of LUTS. For rapid symptom relief, combination with an
alfa blocker may be appropriate. There is strong evidence that
dutasteride has a positive effect not only on disease-oriented
outcomes (e.g. reductions in DHT levels and prostate volume), but
also all important patient-oriented outcomes (including symptom
relief, and avoidance of AUR and the need for surgery). 
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